The combination of temsirolimus, a mammalian target of rapamycin inhibitor, and bortezomib, a proteasome inhibitor, is safe and has activity in patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL), a new study published online ahead of print in the journal Cancer has shown.
For the single-arm, phase II trial, researchers enrolled 39 patients with relapsed/refractory B-cell NHL. Participants received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22, of each 35-day cycle.
Results showed that 7.7% (95% CI: 1.6, 21) achieved a complete response and 23% (95% CI: 11, 39) of patients achieved a partial response, which corresponds to an overall response rate of 31% (95% CI: 17, 48).
Researchers found that median progression-free survival was 4.7 months (95% CI: 2.1, 7.8). Specifically, median progression-free survival was 2 months for patients with diffuse large B-cell lymphoma, 7.5 months for patients with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma.
RELATED: Polatuzumab Plus Rituximab May Be Safe, Effective for Follicular Lymphoma
In regard to safety, there were no unexpected treatment-related toxicities.
The findings suggest that further studies are warranted to evaluate this combination in certain subtypes of NHL, particularly follicular lymphoma.